Haematological Cancers

Disease

Also known as: haematological cancers

Related News

Roche's Gazyva Meets Primary Endpoint in Phase III Trial for Primary Membranous Nephropathy

Feb 16, 2026

Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.

Roche's Gazyva Meets Primary Endpoint in Phase III Kidney Disease Trial

Feb 16, 2026

Roche announced that Gazyva/Gazyvaro met its primary endpoint in the Phase III MAJESTY study for primary membranous nephropathy, showing statistically significant complete remission rates versus tacrolimus. The drug could become the first approved therapy for this rare autoimmune kidney disease.